BeStock  
Stocks › Biotechnology › LEGN

Legend Biotech LEGN

US equityMarket cap rank #2439BiotechnologyChina Concept Stocks
$15.25 −$0.85 (-5.28%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $15.44 +1.25%
Open$15.95
Prev close$16.10
Day range$15.15 – $16.13
Volume3.42M
Market cap$2.96B
P/E (TTM)–
Dividend yield–

LEGN Stock News

Headlines matching Legend Biotech or the LEGN ticker, most recent first.

  • H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $65Market news · 30 Sep 2026 · Direct mention
  • RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $58Market news · 11 Sep 2026 · Direct mention
  • Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $74 NegativeMarket news · 11 Sep 2026 · Direct mention
  • UBS Maintains Legend Biotech(LEGN.US) With Hold Rating, Maintains Target Price $28Market news · 14 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $48Market news · 13 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $65Market news · 12 Aug 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)TipRanks · 12 Aug 2026 · Direct mention
  • Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), Legend Biotech (LEGN) and Mineralys Therapeutics, Inc. (MLYS)TipRanks · 12 Aug 2026 · Direct mention
  • RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $63 NegativeMarket news · 7 Jul 2026 · Direct mention
  • RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $59 NegativeMarket news · 27 Jul 2026 · Direct mention
  • UBS Downgrades Legend Biotech(LEGN.US) to Hold Rating, Cuts Target Price to $28 NegativeMarket news · 24 Jul 2026 · Direct mention
  • Goldman Sachs Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $40.5 NegativeMarket news · 16 Jul 2026 · Direct mention
  • Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $80Market news · 14 Jul 2026 · Direct mention
  • J.P. Morgan Downgrades Legend Biotech(LEGN.US) to Hold Rating, Cuts Target Price to $35 NegativeMarket news · 13 Jul 2026 · Direct mention
  • UBS Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $49Market news · 5 Jun 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on LEGN.

Sign in to join the discussion.

Scroll to Top